HOME >> MEDICINE >> NEWS
ACTG Protocol 185 Enrollment Halted

Enrollment has been stopped in a clinical trial of mother to child HIV transmission, Pediatric ACTG Protocol 185, due to a welcome but unexpectedly low rate of infant infection which made comparison of the standard and experimental treatments impossible. Pediatric ACTG Protocol 185 was a randomized, controlled clinical trial designed to test whether HIVIG (an immune globulin containing high levels of antibodies to HIV) reduced transmission of HIV from infected pregnant women to their infants when added to the standard AZT-based preventive treatment regimen. The comparison group received AZT and standard intravenous immunoglobulin (IVIG) that does not contain HIV antibodies.

Although enrollment will be stopped, the trial will continue with the standard AZT treatment and followup of mothers and children, it was announced by the study's sponsors, the National Heart, Lung and Blood Institute; the National Institute of Child Health and Human Development, and the National Institute of Allergy and Infectious Diseases.

The trial allowed enrollment of HIV-infected women with more advanced disease and lower CD4+ T cell count than had Pediatric ACTG Protocol 076, the 1994 clinical trial that demonstrated that AZT decreases mother-to-child HIV transmission by two-thirds. The Pediatric ACTG Protocol 185 trial enrolled HIV-infected pregnant women with CD4+ T cell count less than or equal to 500/mm3 who were receiving AZT during pregnancy for medical indications. Women could receive other nucleoside antiretroviral agents, if required, for their own health. It was anticipated that transmission from mother to child in a population of women with advanced disease, even when receiving AZT, would be significantly higher than that observed in women with less severe disease receiving AZT (in Pediatric ACTG Protocol 076, the transmission rate was 7.6% from AZT-receiving women).

On March 21, 1997, the study's independent Data and Safety Monitoring Board (DSMB) review
'"/>

Contact: Robert Bock
bockr@HD03.nichd.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development
26-Mar-1997


Page: 1 2 3 4

Related medicine news :

1. Forest mapping from space supports Kyoto Protocol
2. Enrollment begins for osteoarthritis initiative
3. Enrollment in cancer trials not linked to better health outcomes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ACTG Protocol Enrollment Halted

(Date:5/20/2013)... 20, 2013 A pioneer and ... solutions, i2i Systems announced today that ... Foundation (SCF) selected i2iTracks as their population management ... meet their Meaningful Use (MU), Government Performance and ... requirements – a welcomed solution to managing the ...
(Date:5/20/2013)... T.E.N. announced today that it ... Information Security Executive® Northeast Awards now through Friday, ... Information Security Executive® of the Year and ISE® ... made a positive impact on their organizations through ... information security; and the ISE® Project of the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 6Webs.com is ... alarm system reviews . 6Webs.com recently completed their assessments ... nation. Reviews are completed annually and the top home ... which include their monitoring technology, equipment and warranties to ... stated, "When the 6Webs.com team completed the home security ...
(Date:5/20/2013)... NV (PRWEB) May 20, 2013 WEDI, ... to improve the exchange of healthcare information, announced today ... creation of the WEDI ICD-10 State Collaborative Initiative. The ... their members in order to increase efficiencies and reduce ... , The goal of the new initiative is to ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Selexis SA, ... lead identification and cell line development for scale-up and ... Company’s co-founder will present data on the Company’s core ... & Engineering Conference, May 20 - 23 at the ... California. Selexis’ co-founder and scientific advisory board member, Nicolas ...
Breaking Medicine News(10 mins):Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 2Health News:Baldrige Award Winner Southcentral Foundation Selects i2iTracks Population Health Intelligence Solution to Support Meaningful Use, GPRA and UDS Reporting Requirements 3Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 3Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:WEDI Launches New ICD-10 State Collaborative Initiative to Increase Efficiencies and Reduce Compliance Time and Costs 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3
(Date:5/20/2013)... 20, 2013  TRACE International today released its ... that prosecutions against individuals and government or business entities ... GER 2012 is the third in an ... trends. "Although the number of outbound enforcement ... remained a priority," said Alexandra Wrage ...
(Date:5/20/2013)... NEW YORK , May 20, 2013  Echo ... Rule 2.5 of the Irish Takeover Rules (the "Announcement"), ... Corporation, plc (NYSE: ELN ) to $12.50 ... financed, cash confirmed and not conditional on due diligence.  ... eliminated.  Royalty Pharma has reserved the right to waive ...
(Date:5/20/2013)... , May 20, 2013 A medical ... use both in space and on Earth was inducted ... The technology assures high quality, secure handling ... low-power ultrasound units, like those used in hospitals and ... the diagnostic imaging solution of choice for human space ...
Breaking Medicine Technology:TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3
Cached News: